Liquidia Corporation Upgraded to Strong Buy by Raymond James
Shares of Liquidia Corporation (LQDA) rose for a third consecutive session following an upgrade by Raymond James. Analyst Ryan Deschner raised the stock's rating from Neutral to Strong Buy, signaling increased confidence in the company's trajectory. The upgrade is primarily driven by expectations surrounding the commercial rollout of Yutrepia, Liquidia's therapy designed to treat pulmonary arterial hypertension (PAH). The market response suggests investor optimism regarding the drug's potential to capture market share and drive revenue growth.
Tickers: $LQDA